Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Erlotinib |
Synonyms | |
Therapy Description |
Tarceva (erlotinib) is a first-generation EGFR inhibitor that blocks EGFR signaling, potentially leading to inhibition of tumor growth (PMID: 30069756). Tarceva (erlotinib) is FDA approved for use in patients with non-small cell lung cancer harboring EGFR exon 19 deletions and/or EGFR L858R, and in combination with gemcitabine for patients with locally advanced, unresectable, or metastatic pancreatic cancer (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Erlotinib | Tarceva | CP358774 | EGFR Inhibitor (Pan) 64 EGFR Inhibitor 1st gen 3 | Tarceva (erlotinib) is a first-generation EGFR inhibitor that blocks EGFR signaling, potentially leading to inhibition of tumor growth (PMID: 30069756). Tarceva (erlotinib) is FDA approved for use in patients with non-small cell lung cancer harboring EGFR exon 19 deletions and/or EGFR L858R, and in combination with gemcitabine for patients with locally advanced, unresectable, or metastatic pancreatic cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ROS1 rearrange | lung non-small cell carcinoma | no benefit | Erlotinib | Guideline | Actionable | EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ROS1 rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org). | detail... |
ALK rearrange | lung non-small cell carcinoma | no benefit | Erlotinib | Guideline | Actionable | EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ALK rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01592383 | Phase II | Erlotinib | Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma | Completed | USA | 0 |
NCT02091141 | Phase II | Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab | My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | Completed | USA | 0 |
NCT02770014 | Phase II | Erlotinib | Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer | Terminated | USA | 0 |
NCT02193282 | Phase III | Erlotinib | Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) | Active, not recruiting | USA | 1 |
NCT02277457 | Phase I | Crizotinib Erlotinib | Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations | Withdrawn | USA | 0 |
NCT00997334 | Phase II | Erlotinib | Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC | Completed | USA | 0 |
NCT04341181 | Phase II | Atezolizumab Niraparib Erlotinib Axitinib Cobimetinib + Vemurafenib Avelumab Pertuzumab + Trastuzumab Vismodegib Alectinib Ado-trastuzumab emtansine | ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling (ProTarget) | Recruiting | DNK | 0 |
NCT03297606 | Phase II | Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) | Recruiting | CAN | 0 |
NCT02961374 | Phase II | Erlotinib | Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer | Completed | USA | 1 |
NCT02186301 | Phase II | Rociletinib Erlotinib | TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy | Terminated | USA | ITA | ESP | DEU | 3 |
NCT00547105 | Phase II | Erlotinib | Erlotinib and Stereotactic Body Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Non-Small Call Lung Cancer | Completed | USA | 0 |
NCT02154490 | Phase II | Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab Fexagratinib Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer | Completed | USA | CAN | 0 |
NCT02117024 | Phase II | Cyclophosphamide + HS-110 Pemetrexed Disodium Vinorelbine Erlotinib Gemcitabine Docetaxel Paclitaxel | A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02194738 | Phase I | Nivolumab Crizotinib Erlotinib | Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | Recruiting | USA | 2 |
NCT01344824 | Phase II | Bevacizumab Erlotinib Carboplatin Pemetrexed Disodium | Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers | Completed | USA | 0 |
NCT01967095 | Phase I | Erlotinib | Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer | Completed | USA | 0 |
NCT02574078 | Phase Ib/II | Crizotinib + Nivolumab Erlotinib + Nivolumab Nivolumab + Pemetrexed Disodium Bevacizumab Carboplatin + Pemetrexed Disodium Bevacizumab + Nivolumab Nivolumab Erlotinib Carboplatin + Paclitaxel Carboplatin + Docetaxel Carboplatin + Nab-paclitaxel Carboplatin + Gemcitabine Paclitaxel Docetaxel Pemetrexed Disodium Gemcitabine | A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate370) | Completed | USA | 0 |
NCT02355431 | Phase II | Erlotinib Itacitinib | INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations | Withdrawn | USA | 0 |
NCT01801111 | Phase II | Erlotinib Alectinib | A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment | Completed | USA | SWE | NLD | LUX | ITA | GBR | FRA | ESP | DNK | DEU | BEL | AUS | 4 |
NCT01116336 | Phase I | Erlotinib | Phase I Chemoprevention Trial With Green Tea Polyphenon E and Erlotinib in Patients With Premalignant Lesions of the Head and Neck | Completed | USA | 0 |
NCT02588261 | Phase III | Naquotinib Gefitinib Erlotinib | A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations | Terminated | USA | ROU | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 11 |
NCT01233687 | Phase Ib/II | Rilotumumab Erlotinib | AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT03137771 | Phase II | Docetaxel Pemetrexed Disodium Gemcitabine Erlotinib | Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | Active, not recruiting | USA | ISR | CAN | 1 |
NCT02318368 | Phase II | Erlotinib Erlotinib + Ficlatuzumab | A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label | Terminated | USA | ITA | AUS | 4 |
NCT02450591 | Phase I | Erlotinib | Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations | Completed | USA | 0 |
NCT01197170 | Phase I | Erlotinib Everolimus Sorafenib Anastrozole Bevacizumab | Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance | Completed | USA | 0 |
NCT02015728 | Phase I | Erlotinib Everolimus Dasatinib Etoposide + Temozolomide Sorafenib | Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors | Unknown status | USA | 0 |
NCT00301418 | Phase Ib/II | Erlotinib | Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma | Completed | USA | 0 |
NCT01454102 | Phase I | Bevacizumab Ipilimumab Cisplatin Pemetrexed Disodium Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab | Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | Completed | USA | CAN | 0 |
NCT01306045 | Phase II | Erlotinib Lapatinib MK2206 Sunitinib Selumetinib | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | Completed | USA | 0 |
NCT02352948 | Phase III | Durvalumab Vinorelbine Durvalumab + Tremelimumab Gemcitabine Erlotinib Tremelimumab | A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC) | Completed | USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BGR | BEL | AUS | 9 |
NCT01064479 | Phase II | Erlotinib Carboplatin Docetaxel Cisplatin | Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck | Completed | USA | 0 |
NCT02296125 | Phase III | Erlotinib Osimertinib Gefitinib | AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA) | Active, not recruiting | USA | TUR | SWE | ROU | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUS | 11 |
NCT02551718 | Phase I | Bosutinib Irinotecan Romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia | Completed | USA | 0 |
NCT01248247 | Phase I | Erlotinib MK2206 + Selumetinib Sorafenib Erlotinib + MK2206 | BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study | Completed | USA | 0 |
NCT02152631 | Phase III | Erlotinib Abemaciclib | A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER) | Active, not recruiting | USA | TUR | ROU | POL | ITA | ISR | GRC | FRA | ESP | DEU | CAN | BRA | AUT | ARG | 7 |
NCT02134886 | Phase I | Erlotinib | Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection | Terminated | USA | 0 |
NCT02134015 | Phase III | Erlotinib Erlotinib + Patritumab | Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) | Terminated | USA | POL | ITA | HUN | GBR | ESP | DEU | CZE | CAN | BEL | 0 |
NCT01456325 | Phase III | Erlotinib Onartuzumab | A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung) | Completed | USA | POL | NLD | ITA | ISR | IRL | HUN | HRV | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 10 |
NCT01471964 | Phase Ib/II | Erlotinib Alisertib | Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02169284 | Phase II | Erlotinib | Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery | Terminated | USA | 0 |
NCT01857271 | Phase II | Erlotinib | Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT01472016 | Phase I | Docetaxel ABT-700 Cetuximab Erlotinib Fluorouracil + Irinotecan + Leucovorin | Study of ABT-700 in Subjects With Advanced Solid Tumors | Completed | 0 | |
NCT01455389 | Phase Ib/II | Quaratusugene Ozeplasmid Erlotinib Diphenhydramine Dexamethasone | FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer | Terminated | USA | 0 |
NCT02411448 | Phase III | Erlotinib Gefitinib + Ramucirumab Erlotinib + Ramucirumab Osimertinib + Ramucirumab | A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (RELAY) | Active, not recruiting | USA | TUR | ROU | ITA | GRC | GBR | FRA | ESP | DEU | CAN | 4 |
NCT02004262 | Phase II | Irinotecan Erlotinib Cyclophosphamide Capecitabine + Fluorouracil + Gemcitabine | Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting | Completed | USA | CAN | 0 |
NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed | USA | 0 |
NCT02468661 | Phase I | Capmatinib Capmatinib + Erlotinib Erlotinib Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification | Terminated | USA | NLD | ITA | FRA | ESP | DEU | BEL | 3 |
NCT03878524 | Phase I | Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab | A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) | Terminated | USA | 0 |
NCT00054496 | Phase II | Erlotinib | Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme | Unknown status | USA | 0 |
NCT01573702 | Phase II | Erlotinib | Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) | Completed | USA | 0 |
NCT04591431 | Phase II | Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) | Active, not recruiting | ITA | 0 |